Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. Show more

Location: 2400 Skymark Avenue, Mississauga, ON, L4W 5K5, Canada | Website: https://www.profoundmedical.com | Industry: Medical Devices | Sector: Healthcare


Market Cap

132.3M

52 Wk Range

$3.90 - $9.17

Previous Close

$4.36

Open

$4.37

Volume

36,319

Day Range

$4.31 - $4.48

Enterprise Value

102.3M

Cash

35.2M

Avg Qtr Burn

-8.683M

Insider Ownership

17.35%

Institutional Own.

45.98%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date